All News

Long lasting weight reduction was reported in individuals that were treated with tirzepatide with diet and exercise, compared to placebo.

Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.

Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.

Patients with previously untreated HLA-A*02:01+ mUM saw improvements in OS, PFS, and ctDNA clearance.

Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.

Vanderbilt Specialty Pharmacy and Takeda Oncology are reaching across silos and entering an innovative partnership to improve patient care across the entire medication journey.

Although a residency is beneficial for traditional career paths, a career can be more than working inside a pharmacy.

Collaborating with patient advocacy organizations offers pharmacy students a unique opportunity to make a meaningful impact in health care.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.

Rimple Gabri, PharmD, a pharmacist with Giant Pharmacy for nearly 3 decades, shares her journey into the pharmacy profession.

The trial data showed ongoing clinical benefit in patients with advanced endometrial cancer who completed pembrolizumab and continued on lenvatinib vs chemotherapy alone.

Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.

Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.

Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.

Taking pharmacists out of the dispensing setting and placing them in communities as educators on drug safety is reaping rewards.

This is the first phase 3 trial to evaluate a KRAS G12C-inhibitor plus an anti-epidermal growth factor receptor antibody for this type of colorectal cancer.

The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.

Risk of long COVID was 3 times higher in those who had pre-existing conditions and a short sleep duration, compared to those with no pre-existing conditions and adequate sleep.

Oncology leaders and pharma representatives discuss collaboration best practices.

mRNA-1083 is an investigational combination vaccine designed to prevent influenza and COVID-19.

Jessica McMakin, PharmD, and Marina Mangham, CPhT, enjoy providing personalized service to their local community

Not only did taletrectinib shrink tumors in 92% of patients who were tyrosine kinase inhibitor -naïve, but 89.5% of patients continued to respond to treatment at 12 months.

Vanessa Campbell, PharmD, the director of Clinical Pharmacy at UPMC Health Plan, discusses her role and responsibilities, which include managing a team of pharmacists involved in patient outreach and clinical disease state management.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.